CRISPR/Cas9-modified Human T Cell (PD-1 and ACE2 Knockout Engineered T Cells)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CRISPR/Cas9-modified Human T Cell (PD-1 and ACE2 Knockout Engineered T Cells), covering 2021-08-16 to 2021-08-16. Get the full timeline:
Most recent: Clinical Trial Update: CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients [Phase 1, Phase 2]